A Novel Strategy for Inhibiting Growth of Human Pancreatic Cancer Cells by Blocking Cyclin-Dependent Kinase Activity

Hideaki Iseki, Tien C. Ko, Xiang Ying Xue, Annie Seapan, Courtney Townsend

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Pancreatic cancers frequently carry mutations in the K-ras, p53, and p16 genes, which regulate cell proliferation. Transition from G1 to S phase of the cell cycle requires activation of cyclin-dependent kinase 2 (Cdk2), which is inhibited by olomoucine and roscovitine. The purpose of this study was to determine whether olomoucine and roscovitine can block Cdk2 kinase activity and inhibit proliferation of four human pancreatic cancer cell lines with various genetic alterations. Human pancreatic carcinoma cell lines BxPC-3, PANC-1, Capan-2, and CAV were treated with olomoucine or roscovitine. Cdk2 kinase activity was determined using histone H1 as the substrate. Cell cycle distribution was analyzed by DNA flow cytometry. Cell numbers were quantitated by Coulter counter. Olomoucine and roscovitine blocked Cdk2 activity in all four pancreatic cancer cell lines. Both compounds also inhibited cell proliferation in a dose-dependent fashion. Roscovitine was at least threefold more potent than olomoucine for both Cdk2 activity and cell proliferation. We have shown that Cdk inhibitors, olomoucine and roscovitine, block proliferation of human pancreatic cancer cells regardless of their mutations in K-ras, p53, or p16 genes. These compounds represent a novel therapeutic strategy with potential therapeutic benefits for pancreatic cancers.

Original languageEnglish (US)
Pages (from-to)36-43
Number of pages8
JournalJournal of Gastrointestinal Surgery
Volume2
Issue number1
StatePublished - Jan 1998

Fingerprint

Cyclin-Dependent Kinase 2
Cyclin-Dependent Kinases
Pancreatic Neoplasms
Growth
p16 Genes
ras Genes
p53 Genes
Cell Proliferation
Cell Line
Cell Cycle
Phosphotransferases
Mutation
S Phase
Histones
olomoucine
roscovitine
Flow Cytometry
Cell Count
DNA
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

A Novel Strategy for Inhibiting Growth of Human Pancreatic Cancer Cells by Blocking Cyclin-Dependent Kinase Activity. / Iseki, Hideaki; Ko, Tien C.; Xue, Xiang Ying; Seapan, Annie; Townsend, Courtney.

In: Journal of Gastrointestinal Surgery, Vol. 2, No. 1, 01.1998, p. 36-43.

Research output: Contribution to journalArticle

@article{f2869f1c56574c869c231c55aec3a649,
title = "A Novel Strategy for Inhibiting Growth of Human Pancreatic Cancer Cells by Blocking Cyclin-Dependent Kinase Activity",
abstract = "Pancreatic cancers frequently carry mutations in the K-ras, p53, and p16 genes, which regulate cell proliferation. Transition from G1 to S phase of the cell cycle requires activation of cyclin-dependent kinase 2 (Cdk2), which is inhibited by olomoucine and roscovitine. The purpose of this study was to determine whether olomoucine and roscovitine can block Cdk2 kinase activity and inhibit proliferation of four human pancreatic cancer cell lines with various genetic alterations. Human pancreatic carcinoma cell lines BxPC-3, PANC-1, Capan-2, and CAV were treated with olomoucine or roscovitine. Cdk2 kinase activity was determined using histone H1 as the substrate. Cell cycle distribution was analyzed by DNA flow cytometry. Cell numbers were quantitated by Coulter counter. Olomoucine and roscovitine blocked Cdk2 activity in all four pancreatic cancer cell lines. Both compounds also inhibited cell proliferation in a dose-dependent fashion. Roscovitine was at least threefold more potent than olomoucine for both Cdk2 activity and cell proliferation. We have shown that Cdk inhibitors, olomoucine and roscovitine, block proliferation of human pancreatic cancer cells regardless of their mutations in K-ras, p53, or p16 genes. These compounds represent a novel therapeutic strategy with potential therapeutic benefits for pancreatic cancers.",
author = "Hideaki Iseki and Ko, {Tien C.} and Xue, {Xiang Ying} and Annie Seapan and Courtney Townsend",
year = "1998",
month = "1",
language = "English (US)",
volume = "2",
pages = "36--43",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - A Novel Strategy for Inhibiting Growth of Human Pancreatic Cancer Cells by Blocking Cyclin-Dependent Kinase Activity

AU - Iseki, Hideaki

AU - Ko, Tien C.

AU - Xue, Xiang Ying

AU - Seapan, Annie

AU - Townsend, Courtney

PY - 1998/1

Y1 - 1998/1

N2 - Pancreatic cancers frequently carry mutations in the K-ras, p53, and p16 genes, which regulate cell proliferation. Transition from G1 to S phase of the cell cycle requires activation of cyclin-dependent kinase 2 (Cdk2), which is inhibited by olomoucine and roscovitine. The purpose of this study was to determine whether olomoucine and roscovitine can block Cdk2 kinase activity and inhibit proliferation of four human pancreatic cancer cell lines with various genetic alterations. Human pancreatic carcinoma cell lines BxPC-3, PANC-1, Capan-2, and CAV were treated with olomoucine or roscovitine. Cdk2 kinase activity was determined using histone H1 as the substrate. Cell cycle distribution was analyzed by DNA flow cytometry. Cell numbers were quantitated by Coulter counter. Olomoucine and roscovitine blocked Cdk2 activity in all four pancreatic cancer cell lines. Both compounds also inhibited cell proliferation in a dose-dependent fashion. Roscovitine was at least threefold more potent than olomoucine for both Cdk2 activity and cell proliferation. We have shown that Cdk inhibitors, olomoucine and roscovitine, block proliferation of human pancreatic cancer cells regardless of their mutations in K-ras, p53, or p16 genes. These compounds represent a novel therapeutic strategy with potential therapeutic benefits for pancreatic cancers.

AB - Pancreatic cancers frequently carry mutations in the K-ras, p53, and p16 genes, which regulate cell proliferation. Transition from G1 to S phase of the cell cycle requires activation of cyclin-dependent kinase 2 (Cdk2), which is inhibited by olomoucine and roscovitine. The purpose of this study was to determine whether olomoucine and roscovitine can block Cdk2 kinase activity and inhibit proliferation of four human pancreatic cancer cell lines with various genetic alterations. Human pancreatic carcinoma cell lines BxPC-3, PANC-1, Capan-2, and CAV were treated with olomoucine or roscovitine. Cdk2 kinase activity was determined using histone H1 as the substrate. Cell cycle distribution was analyzed by DNA flow cytometry. Cell numbers were quantitated by Coulter counter. Olomoucine and roscovitine blocked Cdk2 activity in all four pancreatic cancer cell lines. Both compounds also inhibited cell proliferation in a dose-dependent fashion. Roscovitine was at least threefold more potent than olomoucine for both Cdk2 activity and cell proliferation. We have shown that Cdk inhibitors, olomoucine and roscovitine, block proliferation of human pancreatic cancer cells regardless of their mutations in K-ras, p53, or p16 genes. These compounds represent a novel therapeutic strategy with potential therapeutic benefits for pancreatic cancers.

UR - http://www.scopus.com/inward/record.url?scp=0031598765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031598765&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 36

EP - 43

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 1

ER -